^
Association details:
| Biomarker: | HER-2 G778_P780dup |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
Excerpt:
...49-year-old Caucasian, non-smoking woman was diagnosed with stage IV right upper-lobe lung adenocarcinoma…Additional genomic analysis revealed an insertional duplication (p.Gly778_Pro780dup) in exon 20 of the HER2 gene…Within 2 weeks of starting afatinib (50 mg/day), the patient had a rapid clinical and symptomatic response, with disappearance of all disease-related symptoms, as well as overall SD with a radiological response in liver and pleura, which was maintained for 3 months.
DOI:
10.1016/j.lungcan.2012.01.008
